11/7/26 The Plausible Mechanism Pathway: A New Evidence Playbook for Rare Disease Development Previous Write Your Own Endpoint Justification Next Leveraging Natural History and RWE for Rare Approvals You Might Also Like One Shot, No Slack: The Clinical Decisions That Make or Break a Rare Disease Program Retention by Design - Keeping Families Engaged for Multi-Year Studies Commercial Success in Rare Disease Takes an Ecosystem: Aligning Manufacturers, Specialty Pharmacy, Providers, and Patient Support Myth-Busting Hybrid & Home-Based Trials: What’s Real, What’s Not and What Scales Leveraging Natural History and RWE for Rare Approvals
11/7/26 The Plausible Mechanism Pathway: A New Evidence Playbook for Rare Disease Development Previous Write Your Own Endpoint Justification Next Leveraging Natural History and RWE for Rare Approvals You Might Also Like One Shot, No Slack: The Clinical Decisions That Make or Break a Rare Disease Program Retention by Design - Keeping Families Engaged for Multi-Year Studies Commercial Success in Rare Disease Takes an Ecosystem: Aligning Manufacturers, Specialty Pharmacy, Providers, and Patient Support Myth-Busting Hybrid & Home-Based Trials: What’s Real, What’s Not and What Scales Leveraging Natural History and RWE for Rare Approvals
